

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 18, 2021

**PRESSURE BIOSCIENCES, INC.**

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

(State or Other Jurisdiction of Incorporation)

001-38185

(Commission  
File Number)

04-2652826

(IRS Employer  
Identification No.)

14 Norfolk Avenue, South Easton, MA

(Address of Principal Executive Offices)

02375

(Zip Code)

(508) 230-1828

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements are based on the Company's current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. Forward looking statements include, without limitation, statements relating to projected industry growth rates, the Company's current growth rates and the Company's present and future cash flow position. A variety of factors could cause actual events and results, as well as the Company's expectations, to differ materially from those expressed in or contemplated by the forward-looking statements. Risk factors affecting the Company are discussed in detail in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

**Item 7.01 Regulation FD Disclosure.**

Effective August 18, 2021, executives of Pressure BioSciences, Inc. (the "Company") have begun using the materials included in Exhibit 99.1 to this report (the "Investor Presentation") in connection with presentations to existing stockholders of the Company, potential investors of the Company, and the investment community. The Investor Presentation provides an overview of the Company's strategy, performance and future objectives.

The information provided under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is "furnished" and shall not be deemed "filed" with the Securities

and Exchange Commission or incorporated by reference in any filing under the Securities Exchange Act of 1934 or the Securities Act of 1933.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Pressure BioSciences, Inc. Investor Presentation</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 20, 2021

**PRESSURE BIOSCIENCES, INC.**

By: /s/ Richard T. Schumacher

Richard T. Schumacher,  
President and Chief Executive Officer

---



Barocycler™ 2320EXT

# Pressure BioSciences

Commercializing the Gentle Giant  
of Thermodynamics

Investor Presentation  
August 18, 2021

(OTCQB: PBIO)

## FORWARD LOOKING STATEMENTS

This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company's products, technology and other future events and operations. These statements are neither a promise nor guarantee but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward-looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company's filings with the Securities and Exchange Commission.

# Pressure BioSciences, Inc. (OTCQB: PBIO)

Three Enabling High Pressure Platforms Driving Discovery & Quality Improvement in Critical Research & Manufacturing Areas of the Life Sciences



## Pressure Cycling Technology (PCT)

*Alternating Cycles of Hydrostatic Pressure to Control Molecular Interactions*

- Biomarker Discovery, Biotherapeutics Characterization & QC, Diagnostics
- 350 Instruments Installed WW, 225 Customers (Multiple KOLs), >200 Publications, 15 Patents



## BaroFold™ Technology (BaroFold)

*High Pressure Disaggregation and Controlled Refolding of Proteins to Desired Active Structures*

- Bioprocess Development for Novel Protein Biotherapeutics, Rescue/Rework, Scalable for Mfg
- Contract Services Initiated, Six Customer Projects, 8 Patents



## Ultra Shear Technology™ (UST™)

*Intense Shear Forces from Ultra High Pressure Valve Discharge with Controlled Temperatures*

- Nanoemulsification Processing - Makes Oil-Based Products Effectively Water-Soluble
- Dec 2021 Market Release under Lease/License Agreements, 6 Patents
- Multiple \$B Markets: Pharmaceuticals, Nutraceuticals, Cosmetics, Agriculture, Food & Bev



www.pressurebiosciences.com

8/19/2021

3

## Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over \$1,000,000 in Orders in First Month of Operations (8.12.21)

- PBI announced the formation of PBI Agrochem, Inc. (new wholly owned agrochemical subsidiary) in July 2021
- During the past month, PBI has been setting up a U.S. warehousing, processing, and product packaging facility
- In July 2021, Company announced the purchase of over \$500K of specialized proprietary bulk material
- Company plans to purchase \$300-\$500 additional specialized proprietary base bulk material in August/September
- Company has received orders for over \$1,000,000 of eco-friendly agrochem pest control and growth stimulant products
- Company expects the majority of the \$1,000,000 in orders to ship in Q3 2021
- The new Agrochem revenue will be additive to existing PBI core product revenue
- PBI expects it will receive orders for additional 2021 product shipments over the coming weeks and months
- Company believes revenue from new agrochem products will be significant and accretive, beginning in Q3 2021
- PBI believes the combination of its Core and new Agrochem product lines will take it to profitability in 2022



www.pressurebiosciences.com

8/19/2021

4

## Short-Term REVENUE Drivers

### Pressure-Based Core Business

- PCT Platform
- BaroFold Platform
- UST Platform

### PBI Agrochem, Inc. - Revenue Flow Begins Q3 2021

- Recently Formed Wholly Owned Subsidiary of Pressure BioSciences, Inc.
- Currently Operational: Receiving First Batch of Specialized Bulk Material this Week to Process/Ship to Customers
- Purchase of Assets of Eco-Friendly Agrochem Company: PBI Believes the Close is Imminent
- Acquisition Will Result in Significant Additional Revenue Added to PBIO's Existing Revenue in 2021
- Current Line of Key, Oil-based Pesticide and Fertilizer Products - Already High Quality & Impressive
- Future Impact of UST™ on Current Line of Key, Oil-based Products - Could be Highly Significant

Q1 2020	Q1 2021	Incr.	Q2 2020	Q2 2021	Incr.	1H 2020	1H 2021	Q3 2021 (forecast)	Q4 2021 (forecast)
\$253,873	\$559,874	121%	\$268,154	\$608,927	127%	\$522,027	\$1,168,801	Add'l ~\$1M Agro	Add'l >\$1M Agro



www.pressurebiosciences.com

8/19/2021

5

**PLEASE JOIN US ON PBI'S Q2 INVESTOR CALL**

**Q2 2021 Financial Results and Business Update on Thursday, August 19, 2021 @ 4:30 pm EDT**

*Company to Discuss Strong Q2 2021 Financial Results, Give Update on Current Activities, and Take Questions on Aggressive Growth Plan Laid Out for the Company on August 5, 2021*

- Revenue, Operating Income - Q2 & YTD
- Strengthen Financial Position
- Up-list to NASDAQ or NYSE
- Acquisition of Eco-Friendly Agrochem Company
- Expansion of Intellectual Property Estate
- Partnership with The Ohio State University
- Ultra Shear Technology (UST) Platform
- BaroFold Platform
- Pressure Cycling Technology (PCT) Platform



[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

8/19/2021

6



**PCT**

**Pressure Cycling Technology**  
Biomarker Discovery and  
Diagnostics Products



**Baro  
Fold**

**BaroFold Technology**  
Bioprocess Development Products & Services



**UST**

**Ultra Shear Technology**  
Nanoemulsion Technology | Equipment and  
Formulation Services

**Thank You!**



[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

8/19/2021

7